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CS15.1 CMV in transplant recipients
B.-H. Tan*. Department of Internal Medicine, Singapore
General Hospital, Singapore
CMV has long been described as the Achilles heel of
organ transplantation. CMV may produce direct effects
such as fever, and end-organ damage, such as retinitis
and colitis. CMV is also thought to produce indirect
effects such as rejection, diabetes, and perhaps even graft
atherosclerosis (in heart transplant recipients). Advances
in viral diagnostics, plus the availabilty of ganciclovir and
valganciclovir, however, have made CMV less fearsome than
it used to be. In this lecture, we will review the data
on both the prophylactic and pre-emptive modes of CMV
prevention in organ transplant recipients, and ask ourselves
if the technology that is now enabling us to measure host
immunity to CMV has a role in clinical management.
CS15.2 Drug design and development against EV71 and
other enteroviruses
T.W. Lin*. State Key Laboratory on Stress Cell Biology,
School of Life Sciences, Xiamen University, China
Enteroviruses are a family of single stranded, positive
sense RNA virus of Picornaviridae. Although most of the
enterovirus-associated diseases are mild and asymptomatic,
some member in the family can cause severe diseases and
death, especially in the young and immunocompromised.
Enteroviruses are the leading cause of aseptic meningitis
which in turn is the most common central nervous
system infection. Enterovirus 71 (EV71), for example,
is an important pathogen besides polioviruses of the
family. It is emerging as the most signiﬁcant neurotropic
enterovirus in some area of the world in outbreaks and
epidemics. This virus circulates in US, and 26% of the
adults tested in a study had antibody. EV71 was the
leading cause of infectious diseases in China in 2010.
The outbreaks of EV71-associated diseases have been
reported in the United States, Australia, Sweden, Japan,
Bulgaria, Hungary, Malaysia, and other countries. It has been
associated with a variety of clinical diseases, including hand,
foot and mouth disease, herpangina, aseptic meningitis,
encephalitis, poliomyelitis-like paralysis, and even fatal
pulmonary edema or hemorrhage. Eneterovirus-associated
disease can be both acute and chronic. The chronic
diseases include dermatomyositis, polymyositis, dilated
cardiomyopathy, and diabetes mellitus. There is an urgent
need to develop therapeutics against EV71 in particular, and
enteroviruses in general.
Upon infection, a polyprotein is translated from the single
open reading in the genome of an enterovirus, which
is processed into mature proteins by virally encoded
proteinases. These proteinases are not only vital to the
propagation of the virus but important factors in limiting
host defense against the virus infection as well. We carry
out structure-based screening, design, and development
of inhibitors against the enterovirus infection using the
proteinases as the targets. The lead compounds were
generated after hits were identiﬁed by virtual screening,
structure characterization, and medicinal chemistry. The
lead compounds were improved by iterations of structure-
based design, chemical synthesis, and functional assay. The
resulting inhibitors are shown to be capable of inhibiting
virus replication and restore host functions.
CS15.3 More and more coronaviruses after the SARS
epidemic: human coronavirus HKU1 and other
coronaviruses
P.C.Y. Woo*. Department of Microbiology, The University
of Hong Kong, Hong Kong S.A.R.
The recent SARS epidemic has boosted global interest in
the discovery of novel human and animal coronaviruses.
The number of coronavirus species with complete genomes
available has increased from nine in 2003 to about 30 in
2011, of which nine, including human coronavirus HKU1
(Betacoronavirus subgroup A), SARS-related Rhinolophus
bat coronavirus (Betacoronavirus subgroup B), Rhinolophus
bat coronavirus HKU2 (Alphacoronavirus), three bat
coronaviruses of two novel subgroups (C and D) in
Betacoronavirus, and three avian coronaviruses which
constitute a proposed novel genus (Deltacoronavirus) were
sequenced by our laboratory. Recently, we have also
developed a comprehensive database, CoVDB (http://
covdb.microbiology.hku.hk), of annotated coronavirus genes
and genomes, for rapid and accurate batch sequence
retrieval, the cornerstone and bottleneck for comparative
gene or genome analysis. With the increasing amount of
genomes available and the user-friendly database, easy
comparative genome analysis and more speciﬁc blast search
results can be generated for efﬁcient downstream analysis.
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CS16.1 Management of the complications of liver
cirrhosis
H. You*. Liver Research Center, Beijing Friendship Hospital,
Capital Medical University, Beijing, China
Abstract not available
CS16.2 Improving survival in patients with
decompensated cirrhosis
D.N. Amarapurkar *. Department of Gastroenterology and
Hepatology, Bombay Hospital & Medical Research Centre,
Mumbai, India
Liver cirrhosis is deﬁned as development of regenerative
nodules surrounded by ﬁbrous septa in response to chronic
liver injury. This leads to vascular remodeling and giving rise
to portal hypertension and end stage liver disease. Liver
transplantation is the only treatment which improves both
longevity and quality of life in patients with decompensated
liver cirrhosis. However every patient with decompensated
liver cirrhosis is not eligible for transplantation and
it is not available for majority of the patients. Our
current understanding of natural history, pathophysiology
and treatment of complication has resulted in improved
management quality of life and life expectancy in patients
with decompensated liver cirrhosis. Median survival of
patients with compensated cirrhosis is 12 years while that
of decompensated patients is reduced to 2 years. Approx-
imately 5 to 7% of the patients change from compensated
stage to decompensated stage. Portal hypertension (PH)
is a universal consequence of cirrhosis responsible for
most of the complications like esophagogastric varices,
variceal bleeding, ascites, spontaneous bacterial peritonitis,
hepatorenal syndrome and hepatic encephalopathy. PH in
cirrhosis is deﬁned by hepatic venous pressure gradient
(HVPG) more than 5mm of mercury. HVPG is indirect
measure of portal pressure. Now it is clear that HVPG more
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than 10 is signiﬁcant PH above which the complications
like variceal bleed and ascites develop. Currently proposed
classiﬁcation of cirrhosis is based on the degree of PH
and associated clinical features. Development of ascites,
variceal bleed and hepatic encephalopathy is considered
to be decompensated cirrhosis. PH results from increase
in the intrahepatic resistance which has dynamic and ﬁxed
components and it is coupled with increase in the portal
blood ﬂow. Therapeutic interventions which can reduce the
HVPG like non selective beta blockers and Transjugular
intrahepatic porta systemic shunt (TIPS) can be helpful in
combating complications of cirrhosis. And they have been
shown to improve survival. Bacterial infection is common in
cirrhosis with one month mortality of 30%. Oral prophylactic
antibiotics or bowel decontamination have shown to
improve long term outcome in patients with decompensated
cirrhosis. Malnutrition is common in all patients with
cirrhosis. Now it is clear there is no need of restricting
the proteins in these patients. In fact nutritional therapy
can improve survival, reduce the rate of infections, stay in
ICU and hospital, and reduce post operative complications.
Screening for hepatocellular carcinoma (HCC) can pick up
very early disease and survival can be improved in these
patients by offering curative treatment. Therapeutic modal-
ities can reverse the cirrhosis. These modalities according
to the etiology are (1) abstinence for alcoholic cirrhosis,
(2) antiviral therapy for hepatitis B, (3) immunosuppression
for autoimmune hepatitis, (4) relieving biliary obstruction
in patients with secondary biliary cirrhosis, (5) antiviral
therapy for hepatitis C and (6) relieving obstruction in
patients with budd Chiari syndrome. Future therapies like
antiﬁbortic, antiangiogenic and anti coagulants may have
potentials reducing ﬁbrosis, reversing cirrhosis. Stem cell
therapy may be helpful in patients with liver cirrhosis.
CS16.3 New concept in nomenclature, classiﬁcation and
diagnosis of liver failure
Y.M. Wang*. Chongqing, China
Abstract not available
CS16.4 Treatment strategy developments of hepatitis B
with liver failure
Z.L. Gao*. Guangzhou, China
Abstract not available
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PL-001 USP18 stimulates HCV production in vitro:
a novel mechanism for HCV resistance to
interferon therapy
L.M. Chen1 *, J. Sun1, L.-T. Lin2, M.X. Ma1, C. Richardson2,
A. Edwards1, J. Feld1, I. McGilvray1. 1University of Toronto,
2Dalhousie University, Canada
Background: The molecular mechanisms of interferon
resistance in almost 50% of the HCV infected patients remain
unclear. We have previously identiﬁed that upregulation
of interferon stimulated genes (ISGs), such as Interferon
Stimulated Gene15 (ISG15) and Ubiquitin Speciﬁc Protease
18 (USP18) in hepatocytes, predicts treatment failure.
Moreover, silencing USP18 potentiates IFN anti-HCV activity
and increased expression of ISG15 promotes HCV production.
In this study we investigate the role of USP18 in HCV
production.
Methods: We studied the effect of over-expression of
wild type (catalytically active) USP18 or an enzymatically
inactive mutant form of USP18 on HCV RNA replication and
viral production in JFH1 culture system. Levels of various
ISGs and of the critical miRNA 122 were assessed by real-
time PCR, and surface expression of the key HCV entry
receptor, CD81, were quantiﬁed by FACS.
Results: Over-expression of wild type and mutant USP18
increases HCV production at baseline (without IFN) and
blunts the anti-HCV activity of IFNa in the JFH1 infectious
system. While neither ISG expression nor miRNA 122 levels
were unaffected by overexpression of USP18, whether in the
presence or absence of IFNa, surface expression of CD81 was
increased following USP18 over-expression in Huh7.5 cells.
Conclusions: These data indicate that USP18 overexpression
leads to increased HCV production independent of its
catalytic activity, and in concert with increased surface
expression of CD81. Thus, USP18, one of the ISGs increased
in chronic HCV infection, stimulates HCV production and
likely contributes to treatment failure by promoting HCV
cell entry and blunting IFN anti-HCV activity.
OL-001 Clinico-epidemiological proﬁle of patients with
hepatitis C virus infection seen in private
practice clinics in Metro Manila
R. Forroza1 *, E. Labio1, V. Banez1, J. Ong1. 1Philippine
General Hospital, Philippines
Background: Hepatitis C virus (HCV) infection is a major
public health problem worldwide. In the Philippines, there
are few published data on the clinico-epidemiological proﬁle
of patients with HCV infection.
Methodology: Out-patient charts of patients seen from
October 2005 to November 2010 in private practice clinics of
3 gastroenterologists were reviewed. All patients with a pos-
itive anti-HCV and/or HCV-RNA were included. Clinical and
epidemiologic information were collected and analyzed.
Results: Of 49 patients included, 27 (55%) were males.
Mean age at diagnosis was 48.5 years. 26 patients had HCV
genotype data genotype 1 in 16 (61%) patients, genotype
2 in 8 (31%), genotype 4 in 2 (8%). The most common
risk factor was blood transfusion before 1990 identiﬁed in
18 (37%) patients. Other risk factors identiﬁed: injection
drug use (IDU) 7 (14%), hemodialysis (HD) 7 (14%), unknown
11 (23%), others 5 (12%). At presentation, 17 (35%) patients
had advanced HCV-related liver disease 13 cirrhosis only
and 4 hepatocellular carcinoma (HCC). Among 37 evaluable
treatment-naïve patients, 16 (43%) were ineligible for
treatment with advanced HCV-related liver disease (69%)
as the most common reason.
Conclusion: In this study, blood transfusion before 1990,
IDU, and HD were the most common risk factors for
HCV infection. Many patients had advanced liver disease
precluding eligibility for therapy. Screening for HCV among
those with a history of blood transfusion before 1990,
IDU, and HD may help identify HCV-infected patients
early allowing institution of antiviral therapy to prevent
progressive liver disease.
OL-002 Could faluvastatin affect the sustained
virological response in chronic hepatitis C virus
treatment?
M. El-Hamamsy1 *, M. Azmy2, G. Badr2, M. Houssein2.
1Clinical Pharmacy Department, Faculty of Pharmacy, Ain
Shams University, 2Internal Medicine Department Faculty
of Medicine, Al-Azhar University, Egypt
Background: Hepatitis C viral (HCV) infection is the leading
cause of death due to liver disease. Additional agents are
